Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 8/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.32 |
| ▸ | KHK | P50053 | 1/20 | 0.31 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7693188 | 0.84 | TRPV4 (0.47) | TRPV4KHK | |
| SCHEMBL12528259 | 0.77 | AR (0.40) | TRPV4 | |
| SCHEMBL8601376 | 0.75 | HPGD (0.37) | HSD17B1HSD17B2 | |
| SCHEMBL10440534 | 0.75 | ALDH1A1 (0.34) | HSD17B1HSD17B2 | |
| SCHEMBL1128865 | 0.75 | TRPV4 (0.46) | TRPV4ESR1ESR2KHK | |
| SCHEMBL7490441 | 0.72 | CYP11B1 (0.38) | HSD17B1HSD17B2 | |
| SCHEMBL1399737 | 0.71 | ABCB11 (0.34) | — | |
| SCHEMBL1725294 | 0.69 | TRPV4 (0.39) | TRPV4KHK | |
| SCHEMBL11939088 | 0.69 | MAOA (0.33) | TRPV4 | |
| SCHEMBL7688191 | 0.68 | PGR (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | CBR1, CBR3, QSOX1 | TRPV4 3939/4885ESR1 3561/4885ESR2 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.